New pill shows promise for arthritis patients who fail standard treatments
NCT ID NCT07452445
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 4 trial tests ivarmacitinib, a once-daily pill, in 100 adults with moderate-to-severe rheumatoid arthritis who did not improve on standard drugs. The study will measure joint symptom improvement after 12 weeks and monitor safety. Ivarmacitinib works by blocking inflammation signals and has shown high response rates in earlier studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ivarmacitinib (a JAK1 inhibitor drug taken as a pill once daily)
What this could lead to
If successful, this could provide a new second-line treatment option for rheumatoid arthritis patients who do not respond to standard first-line therapies.
What could go wrong
This is a Phase 4 study with only 100 participants, so results may not apply to all patients. Common side effects include infections, anemia, and high cholesterol.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••